BIB
ProShares Ultra NASDAQ Biotechnology·NASDAQ
--
--(--)
--
--(--)
Key Stats
Assets Under Management
90.95MUSD
Fund Flows (1Y)
-3.36MUSD
Dividend Yield
0.71%
Discount/Premium to NAV
0.04%
Shares Outstanding
1.10M
Expense Ratio
0.95%
About ProShares Ultra NASDAQ Biotechnology
Issuer
ProShare Advisors
Brand
ProShares
Inception Date
Apr 7, 2010
Structure
Open-Ended Fund
Index Tracked
NASDAQ Biotechnology Index
Management Style
Passive
Dividend Treatment
Distributes
Distribution Tax Treatment
Ordinary income
Income Tax Type
Capital Gains
Max ST Capital Gains Rate
39.60%
Max LT Capital Gains Rate
20.00%
Primary Advisor
ProShare Advisors LLC
Distributor
SEI Investments Distribution Co.
BIB, having been around since 2010, is a leveraged play on the NASDAQ Biotechnology Index (which is also tracked in unlevered form by iShares' IBB), and is heavily focused on NASDAQ's biotechnology and pharmaceutical firms with a large-cap bias. The fund gains its 2x leveraged exposure to the index through several financial instruments (i.e. equity securities, derivatives and money-market instruments), and rebalances its exposure daily. Like all geared funds that rebalance daily, BIB is meant for short-term trading since compounding effects over the long-term could create vast differences from expected returns—for good or for ill.
Classification
Asset Class
Equity
Category
Sector
Focus
Health Care
Niche
Pharma, Biotech & Life Sciences
Strategy
Exchange-specific
Geography
U.S.
Weighting Scheme
Market Cap
Selection Criteria
NASDAQ-listed
Returns
1-Month | 3-Month | YTD | 1-Year | 3-Year | 5-Year | |
|---|---|---|---|---|---|---|
Price Performance | +5.54% | +21.47% | +8.32% | +47.03% | +42.48% | -20.01% |
NAV Total Return | +0.49% | +16.54% | +2.55% | +45.27% | +38.69% | -24.61% |
Ratings
No data is currently available
Ainvest’s AI-powered ETF Scoring Algorithm, built to help retail investors make smarter, data-driven decisions. Leveraging deep learning, reinforcement learning, and large language models, the algorithm scores ETFs across five key dimensions: Fund Flow, Momentum, Safety, Fundamentals, and Performance. Each factor is weighted by its correlation to future returns, resulting in a single, actionable score. Backtested over five years with consistently strong predictive accuracy. Ainvest brings institutional-grade artificial intelligence to everyday investors—transforming complexity into clarity with every score.
Holdings Analysis
Sector
Healthcare
100.00%
Healthcare
100.00%
Asset
Region
90.4%
9.18%
0.34%
0.07%
Category
Ratio
North America
90.40%
Europe
9.18%
Asia
0.34%
Australasia
0.07%
Investment Style
Mega
Large
Medium
Multi
Small
Value
Blend
Growth
Multi-Cap Growth
Comprises companies of multiple sizes that have high growth potential. These ETFs focus on firms across different market caps with promising growth prospects.
Top 10 Holdings
Symbol
Ratio
NASDAQ BIO INDEX SWAP BNP PARIBAS
40.83%
NASDAQ BIOTECHNOLOGY INDEX SWAP CITIBANK NA
29.03%
NASDAQ BIOTECHNOLOGY INDEX SWAP BANK OF AMERICA NA
23.30%
NASDAQ BIOTECHNOLOGY INDEX SWAP GOLDMAN SACHS INTERNATIONAL
17.35%
NASDAQ BIOTECHNOLOGY INDEX SWAP SOCIETE GENERALE
16.33%
GILD
Gilead Sciences
6.78%
AMGN
Amgen
6.23%
VRTX
Vertex Pharmaceuticals
6.17%
REGN
Regeneron
4.18%
NASDAQ BIOTECHNOLOGY INDEX SWAP UBS AG
4.16%
Top 10 Weight 154.36%
267 Total Holdings
Is SPY better than BIB?
Dividends
Dividend Payout History
Declaration Date | Record Date | Payment Date | Amount |
|---|---|---|---|
| 2025-12-24 | 2025-12-24 | 2025-12-31 | 0.135 |
| 2025-09-24 | 2025-09-24 | 2025-09-30 | 0.181 |
| 2025-06-25 | 2025-06-25 | 2025-07-01 | 0.171 |
| 2025-03-26 | 2025-03-26 | 2025-04-01 | 0.131 |
| 2024-12-23 | 2024-12-23 | 2024-12-31 | 0.396 |
| 2024-09-25 | 2024-09-25 | 2024-10-02 | 0.153 |
| 2024-06-26 | 2024-06-26 | 2024-07-03 | 0.265 |
Show more
How Much Does BIB Pay in Dividends?
Premium/Discount Chart
Assets Under Management
Should I buy BIB?
Fund Flows
